NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Pyxis Oncology, Inc. (PYXS) Stock Analysis

Pyxis Oncology, Inc. (PYXS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PYXS

$3.89

+$0.33 (+9.12%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PYXS with… →

PYXS Key Statistics

As of Sep 4, 2026
Trading
Open
$3.53
Previous Close
$3.57
Day's Range
3.52–4.05
52-Week Range
1.03–5.55
Volume
2.23M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.34
Valuation
Market Cap
$324.46M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
29.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.40
Financials (FY)
Revenue (FY)
$13.86M−14.17%
Net Income (FY)
−$79.62M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
83.41M
1-Year Return
+141.61%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
1.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PYXS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+238.26%
2025−26.28%
2024−13.33%
2023+34.33%
2022−87.78%
2021 (partial year)−16.89%

As of September 4, 2026.

PYXS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$13.86M−$79.62M−574.5%
2024$16.15M−$77.33M−478.9%
2023$0.00−$73.79M—
2022$0.00−$120.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$13.86M$11.47M−$84.42M−$79.62M−574.5%
2024$16.15M$15.67M−$68.50M−$77.33M−478.9%
2023$0.00$0.00−$82.20M−$73.79M—
2022$0.00—−$123.48M−$120.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PYXS Valuation vs Biotechnology Median

Median of 656 stocks
MetricPYXSBiotechnology medianvs median
P/S ratio29.3915.2693% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pyxis Oncology, Inc. (PYXS) at $324.46M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 56 employees.

Over the past 52 weeks the price has ranged from $1.03 to $5.55. The most recent close on file for PYXS is $3.89, dated September 4, 2026. That is +$0.33 (+9.12%) against the previous close. The latest close sits 277.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $13.86M. That is −14.17% against the prior fiscal year, when revenue was $16.15M. The same year closed with a net loss of $79.62M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.4.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $13.86M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 29.39. On price-to-sales that is 92.58% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +141.61%. Measured over 3 years, that is +18.80% a year compounded. The reported beta is 1.34. Daily returns over the trailing 4 years annualize to a volatility of 105.82%.

Growth & Income

The record shows no dividend for PYXS.

2026 is still running; the price is +238.26% year to date. Across the complete calendar years on file, 2023 returned +34.33% and 2022 returned −87.78%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Pyxis Oncology, Inc. (PYXS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pyxis Oncology, Inc. PYXS $324.46M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Pyxis Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Visit website →